Fig. 2

Altered H3 acetylation occurs in multiple brain regions, is accompanied by sirtuin upregulation and is not induced by anti-Parkinson drugs in-vitro. a-c Representative Western blots and quantification plots showing the ratios of quantified densitometric measurements of the indicated proteins in individuals with PD (orange) and controls (blue). GAPDH and β-tubulin serve as loading controls. Values were rescaled [0,1]. Boxplots show the mean of replicates for each individual. The indicated p-values are based on a linear mixed model (see Methods). a, b Acetylated H3K9/14 and H3K27 and total histone protein H3 levels in the cerebellum (a) and striatum (b) from individuals with PD and controls. c Sirtuin proteins in the prefrontal cortex of PD and controls. d Acetylated H3K27 in SH-SY5Y cells, untreated (UT) or treated with different concentrations of the sirtuin inhibitor Sirtinol, or the solvent (DMSO) for 6 h. A representative blot is shown. Boxplots show the quantified ratios of three biological replicates (indicated in different colors) carried out in duplicates, rescaled [0,1]. e Acetylated H3K9/14, H3K27 and total H3 protein in differentiated SH-SY5Y-derived dopaminergic neuron-like cells treated with the histone deacetylase inhibitor Trichostatin A (TSA) or anti-Parkinson drugs used by the PW patients during their last year of life. The numbers indicate the concentration (in μM) of the drug. Carb: Carbidopa; Enta: Entacapone; Ropi: Ropinirole; DOPA: L-Dopa. UT: untreated control. A representative blot is shown. Bar plots show the mean quantified ratios of three biological replicates (rescaled [0,1]). Dots indicate the values of each of the individual replicates